CSF2 and temporal arteritis: Mavrilimumab is a fully human IgG4 monoclonal antibody able to neutralise GM-CSF effects by binding to the GM-CSF receptor alpha chain (GM-CSFRα).31 In a phase 2b trial in patients with rheumatoid arthritis, mavrilimumab showed comparable efficacy to anti-TNFα blocker golimumab and superior efficacy compared with placebo, as well as a good safety profile.32–34 The putative role of GM-CSF in critical steps of GCA pathogenesis suggests therapeutic potential for mavrilimumab in this disease, supported by a recent phase 2 trial.35